Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Propranolol and Etodolac in Ovarian Cancer
NCT06839144Phase 2Recruiting
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Mar 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of propranolol and etodolac in ovarian cancer (2 arms), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoints: Transcriptional Activity in Excised Tumors at Day 0, Transcriptional Activity in Blood Samples at Week 11 and 3 more. Started Mar 2025; status: recruiting.
02
Drugs
propranololetodolac
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06839144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06839144.